Back to Search Start Over

The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD).

Authors :
Raffals LE
Saha S
Bewtra M
Norris C
Dobes A
Heller C
O'Charoen S
Fehlmann T
Sweeney S
Weaver A
Bishu S
Cross R
Dassopoulos T
Fischer M
Yarur A
Hudesman D
Parakkal D
Duerr R
Caldera F
Korzenik J
Pekow J
Wells K
Bohm M
Perera L
Kaur M
Ciorba M
Snapper S
Scoville EA
Dalal S
Wong U
Lewis JD
Source :
Inflammatory bowel diseases [Inflamm Bowel Dis] 2022 Feb 01; Vol. 28 (2), pp. 192-199.
Publication Year :
2022

Abstract

Background: Clinical and molecular subcategories of inflammatory bowel disease (IBD) are needed to discover mechanisms of disease and predictors of response and disease relapse. We aimed to develop a study of a prospective adult research cohort with IBD (SPARC IBD) including longitudinal clinical and patient-reported data and biosamples.<br />Methods: We established a cohort of adults with IBD from a geographically diverse sample of patients across the United States with standardized data and biosample collection methods and sample processing techniques. At enrollment and at time of lower endoscopy, patient-reported outcomes (PRO), clinical data, and endoscopy scoring indices are captured. Patient-reported outcomes are collected quarterly. The quality of clinical data entry after the first year of the study was assessed.<br />Results: Through January 2020, 3029 patients were enrolled in SPARC, of whom 66.1% have Crohn's disease (CD), 32.2% have ulcerative colitis (UC), and 1.7% have IBD-unclassified. Among patients enrolled, 990 underwent colonoscopy. Remission rates were 63.9% in the CD group and 80.6% in the UC group. In the quality study of the cohort, there was 96% agreement on year of diagnosis and 97% agreement on IBD subtype. There was 91% overall agreement describing UC extent as left-sided vs extensive or pancolitis. The overall agreement for CD behavior was 83%.<br />Conclusion: The SPARC IBD is an ongoing large prospective cohort with longitudinal standardized collection of clinical data, biosamples, and PROs representing a unique resource aimed to drive discovery of clinical and molecular markers that will meet the needs of precision medicine in IBD.<br /> (© 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Details

Language :
English
ISSN :
1536-4844
Volume :
28
Issue :
2
Database :
MEDLINE
Journal :
Inflammatory bowel diseases
Publication Type :
Academic Journal
Accession number :
34436563
Full Text :
https://doi.org/10.1093/ibd/izab071